Although CCR2 has been targeted experimentally in models of prostate cancer (Loberg et al., 2007; Kirk et al., 2013), the impact of CCR2 blockade on human prostate fibrosis has not been examined. The gene discussed is CCR2; the disease is prostate carcinoma.